UBS raised the firm’s price target on Teradyne (TER) to $130 from $120 and keeps a Buy rating on the shares following the earnings report. The company struck a much more optimistic tone on a number of new and potentially large opportunities that will begin to ramp in 2026, the analyst tells investors in a research note. UBS upped Q4 estimates following the enrings report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TER:
- Teradyne price target raised to $85 from $80 at Goldman Sachs
- Cautious Hold Rating for Teradyne Amid Competitive Pressures and NVIDIA Expansion Potential
- Teradyne upgraded to Equal Weight from Underweight at Morgan Stanley
- Teradyne’s Strong Semiconductor Testing Performance and Strategic Partnerships Justify Buy Rating
- Teradyne price target raised to $130 from $100 at TD Cowen